

# How to improve?

---


- The **classic approach (EBM)** lead to recommendations that appear **too strict or indifferent** to possible differences among regimens when **cost and convenience** are considered.
- We need to **reconcile the apparent disagreement with a more pragmatic approach.**  
For this reason, guidelines development should imply a better understanding of the epidemiological scenario and clinical needs.
- Also, **proper pharmacoeconomical studies and audits** should guide recommendations (guidelines should not be merely a review of existing literature data)

# *We need ...*

---

*HTA evaluation*

***“Unus pro omnibus,  
omnes pro uno”***



***PDTA***